StratDeck

Two stocks in Healthcare

Genmab A/S vs Ypsomed Holding: profit, growth, debt and price compared

Genmab A/S and Ypsomed Holding are each stronger on 3 of 6 figures: Genmab A/S on sales growth, analysts' view and price trend; Ypsomed Holding on profit margin, debt and price for its expected profit.

Figures as of 18 November 2026Yahoo Finance
Explore Genmab A/S' storyWhere next ↓

Save both stocks to your watchlist and revisit their latest fundamentals.

Genmab A/S and Ypsomed Holding side by side
Genmab A/SGMAB.COYpsomed HoldingYPSN.SW
Net margin17.0%Stronger: 30.4%
Revenue growth, past yearStronger: +16.10%−13.30%
Debt to equity82.1%Stronger: 34.9%
Forward P/E29.9×Stronger: 28.8×
Dividend yield—1.04%
AnalystsStronger: Strong buy · 13Buy · 14
From its 200-day averageStronger: +54.9%+21.2%

Share price over the past year

  • Genmab A/S+77.0%
  • Ypsomed Holding+34.1%

17 Nov 202518 Nov 2026

Genmab A/S or Ypsomed Holding: which is stronger?

  • YPSN.SW

    Which is more profitable?

    Ypsomed Holding keeps more of each sale as profit: 30.4% against 17.0%.

  • GMAB.CO

    Which is growing its sales faster?

    Genmab A/S is growing its sales faster: +16.10% over the past year, against −13.30%.

  • YPSN.SW

    Which has borrowed less?

    Ypsomed Holding has borrowed less: its debt is 34.9% of what its shareholders own, against 82.1% for Genmab A/S.

  • YPSN.SW

    Which costs less for the profit it is expected to make?

    Ypsomed Holding costs less for the profit it is expected to make: 28.8× its forward earnings, against 29.9×.

  • Which pays more in dividends?

    Ypsomed Holding pays 1.04% a year in dividends for what a share costs, where Genmab A/S pays none.

  • GMAB.CO

    Which do analysts rate higher?

    Analysts are warmer on Genmab A/S: Strong buy, against Buy for Ypsomed Holding.

  • GMAB.CO

    Which is in the stronger price trend?

    Genmab A/S' price is in the stronger trend: 54.9% above its 200-day average, against 21.2% above.

What each company does

GMAB.COGenmab A/S

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark.

Reports results on 16 February 2027

YPSN.SWYpsomed Holding

Ypsomed Holding AG, together with its subsidiaries, develops, manufactures, and sells injection and infusion systems for safe and simple self-medication in Switzerland, Europe, North America, and internationally.

Reports results on 19 May 2027

This comparison is just the starting point.

Discover opportunities, understand companies and compare investments in one place. See how StratDeck works

Keep researching

Where next

Every European healthcare comparison

Free email

Up to speed in minutes, four times a week

Every Monday, know what moved AI stocks and what to watch next. Every Wednesday and Friday, find a stock worth a look and learn its story. Every Sunday, catch up on the market's week in two minutes.

Early access

Become a StratDeck founding user

Use StratDeck, tell us what's missing, and help decide what we build next.

100 founding places. Founding users get their first month free, then half price for life: £2.99 a month or £30 a year.